Home / Stocks / Innova Captab Limited
INNOVACAP

Innova Captab Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,005.3

Change

-44.8 (-4.27%)

Open

₹1,050.0

Prev. Close

₹1,050.1

Day High

₹1,052.9

Day Low

₹996.0

Volume Analysis

Traded

78,936

Delivered

36,160

Delivery %

45.81%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (22.0%)
  • •Strong 3-year revenue growth (20.7%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,097.04 ₹1,074.97 ₹1,040.14 ₹1,018.07 ₹983.24 ₹961.17 ₹926.34
Fibonacci ₹1,074.97 ₹1,053.23 ₹1,039.81 ₹1,018.07 ₹996.33 ₹982.91 ₹961.17
Camarilla ₹1,020.95 ₹1,015.73 ₹1,010.52 ₹1,018.07 ₹1,000.08 ₹994.87 ₹989.65

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+36.14%

1 Week

-13.54%

1 Month

+2.56%

3 Months

-7.64%

6 Months

+18.51%

1 Year

+37.31%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹336.23

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.55%

Net margin 8.95% × asset turnover 0.82x × equity multiplier 1.71x

Company Overview

Sector

Healthcare

Market Cap

₹5,938 Cr

P/E (TTM)

35.6

ROE

13.7%

Book Value

₹204.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Innova Captab Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Valuation (30/100) is the weakest area to weigh before deciding. FII holding has been falling.

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

30

Cash Flow

38

Corporate Governance

70

Momentum

58

Institutional Ownership

44

Business Quality

64

Risk & Volatility

71

Liquidity

45

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 32.5% CAGR over last 5 years
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording link shared for Q2 FY2026-27 earnings call held on 16 November 2026.

The Board of the Company at its meeting held on Friday, 13th November, 2026, has approved the unaudited (standalone and consolidated) financial results ....

This is in continuation of our intimation dated 05th November, 2026 wherein we had informed regarding an earnings call scheduled with analysts/investors on Monday, 16th …

Innova Captab posted Q2 FY27 revenue of ₹496.3 crore, EBITDA ₹72.4 crore, PAT ₹42.4 crore.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 283 302 263 294 318 316 315 352 380 450 448 471 496
Expenses + 242 258 225 252 268 270 267 299 329 381 383 398 426
Operating Profit 40 45 38 42 50 47 48 52 52 69 65 73 70
OPM % 14.0% 15.0% 14.0% 14.0% 16.0% 15.0% 15.0% 15.0% 14.0% 15.0% 15.0% 16.0% 14.0%
Other Income + 3 2 6 2 2 4 3 4 4 2 2 2 2
Interest 9 7 1 0 0 0 2 3 6 4 5 4 4
Depreciation 5 5 3 5 5 5 10 11 11 11 11 12 12
Profit before tax 30 35 40 39 47 46 39 43 39 56 51 59 56
Tax % 24.0% 29.0% 27.0% 25.0% 25.0% 25.0% 25.0% 27.0% 24.0% 24.0% 25.0% 25.0% 25.0%
Net Profit + 23 25 29 29 35 34 30 31 30 42 38 44 42
EPS in Rs 5 4 5 5 6 6 5 5 5 7 7 8 7
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 17 25 9 26 12 5 20 19 20 42 42 34 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 356 373 411 801 926 1,081 1,244 1,630 1,865
Expenses + 315 322 356 704 813 927 1,057 1,387 1,588
Operating Profit 41 51 54 96 114 154 186 243 278
OPM % 11.0% 14.0% 13.0% 12.0% 12.0% 14.0% 15.0% 15.0% 15.0%
Other Income + 0 1 1 3 9 12 12 7 8
Interest 6 5 4 6 20 21 2 17 17
Depreciation 11 10 6 8 11 16 25 45 46
Profit before tax 25 38 46 86 92 130 171 188 222
Tax % 20.0% 26.0% 26.0% 25.0% 26.0% 27.0% 25.0% 25.0% —
Net Profit + 20 28 34 64 68 94 128 141 167
EPS in Rs 4 6 7 13 14 16 22 25 29
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 8.0% —
Sales growth — 5 10 95 16 17 15 31 37

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 70 98 133 197 229 774 902 1,034 1,110
Borrowings + 72 54 46 199 237 245 338 344 355
Other Liabilities + 68 81 179 167 191 240 271 401 471
Total Liabilities 223 245 370 575 704 1,316 1,568 1,836 1,994
Fixed Assets + 78 73 79 183 183 358 830 842 840
CWIP 0 0 7 0 22 341 23 16 9
Investments 0 0 0 0 0 0 0 41 83
Other Assets + 144 172 283 392 500 617 716 938 1,062
Total Assets 223 245 370 575 704 1,316 1,568 1,836 1,994
Equity Capital 12 12 12 12 48 57 57 57 57

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 19 31 42 59 67 146 64 117
Cash from Investing Activity + -9 -6 -20 -188 -91 -499 -152 -107
Cash from Financing Activity + -9 -23 -19 125 27 361 92 -22
Net Cash Flow 1 1 3 -5 3 8 4 -12
Free Cash Flow 11 27 23 -21 -11 -141 -108 55
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 68 79 101 83 76 113 47 59

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.9% → 50.9%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 35.22% 26.39% 26.67% 27.48% 28.41% 29.0% 29.2% 28.86% 28.76% 28.74% 28.84% 29.1%
Promoters 50.9% 50.9% 50.9% 50.9% 50.9% 50.9% 50.9% 50.9% 50.9% 50.9% 50.9% 50.9%
FII 3.57% 1.94% 1.19% 1.01% 0.74% 0.35% 0.23% 0.08% 0.1% 0.23% 0.34% 0.85%
DII 10.31% 20.78% 21.24% 20.61% 19.96% 19.77% 19.67% 20.17% 20.24% 20.14% 19.92% 19.16%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Innova Captab Limited (this stock) 5,938 35.6 5.09 13.7%
Fdc Limited 6,177 18.8 2.31 11.5%
Iol Chem And Pharma Ltd 5,587 26.4 2.91 8.41%
Sahajanand Medical Tech L 5,427 75.6 — 10.4%
Artemis Med Service Ltd 5,415 46.2 5.47 12.0%
Nephrocare Health Serv L 6,500 50.8 5.46 8.83%
Orchid Pharma Limited 5,296 293.0 2.95 1.49%

Which Mutual Funds Hold Innova Captab Limited?

Frequently Asked Questions about Innova Captab Limited

Community Sentiment

What are other investors saying about Innova Captab Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.